He is the clinical lead of the Arrhythmia Services and the research lead of the Arrhythmia Group across the Royal Brompton and Harefield sites.

Dr Tom Wong’s career focuses on providing the best clinical care to patients with heart rhythm abnormalities and exploring avenues to further improve care through research and innovation.

His research program relates to his clinical interests to seek better understanding and treatment of arrhythmias in advanced disease states and complex cardiac anatomies, particular through catheter-based interventions.

Dr Tom Wong conducted ARC-HF clinical trial, first to show the beneficial effects of catheter ablation in cardiopulmonary performance compared to drug therapy in patients with persistent atrial fibrillation and heart failure. He published the cost impact of the left atrial appendage closure in stroke prevention based upon the UK cost model to inform the economic benefit, beyond the clinical needs, of this treatment to patient at risk of having stroke in UK. He is the chief investigator of CASA-AF trial, funded by NIHR, to compare catheter and thoracoscopic ablation approaches to treat persistent atrial fibrillation. In addition, he has and continue to investigate novel mapping, ablation and device related technologies with an aim to improve clinical outcomes.